Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of camrelizumab plus dalpiciclib in relapsed or refractory non-Hodgkin lymphoma
ChiCTR1900020597Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and dalpiciclib in non-Hodgkin lymphoma (NHL), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
camrelizumabdalpiciclib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ChiCTR1900020597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020597.